EQUITY SECURITIES PORTFOLIO INVESTMENT (Tables)

3 Months Ended

Mar. 31, 2022

Investments, Debt and Equity Securities [Abstract]

Unrealized Gain (Loss) on Investments

Equity securities at fair value for the periods presented were comprised of the following:

Security Type	Cost		Gross Unrealized Gain		Gross Unrealized Loss		Fair Value
	(In thousands)
March 31, 2022:
Equity securities - Life Sciences Portfolio (Note 3)	$	48,279	$	92,253	$	(2,570)	$	137,962
Equity securities - other common stock	108,489		11,822		(11,789)		108,522
Total	$	156,768	$	104,075	$	(14,359)	$	246,484
December 31, 2021:
Equity securities - Life Sciences Portfolio (Note 3)	$	56,037	$	262,811	$	(1,488)	$	317,360
Equity securities - other common stock	43,822		2,068		(1,472)		44,418
Total	$	99,859	$	264,879	$	(2,960)	$	361,778

The following unrealized and realized gains or losses from our investment in the Life Sciences Portfolio are recorded in the change in fair value of equity securities and gain or loss on sale of equity securities, respectively, in the consolidated statements of operations:

	Three Months Ended March 31,
	2022		2021
	(In thousands)
Change in fair value of equity securities of public companies	$	(171,640)	$	5,374
Change in fair value of equity securities without readily determinable fair value	—		31,802
Gain (loss) on sale of equity securities of public companies	59,488		—
Net realized and unrealized (loss) gain	$	(112,152)	$	37,176